PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer

• Published in: Research and reports in urology 2023-01, Vol.15, p.149-155
• Main Authors: Warli, Syah Mirsya, Warli, Muhammad Haritsyah, Prapiska, Fauriski Febrian
• Format: Article
• Language: English
• Subjects: Original Research; pca3; prostate cancer; psa; tmprss2:erg; urine biomarker
• ISSN: 2253-2447; 2253-2447
• DOI: 10.2147/RRU.S401131

Prostate cancer is a highly prevalent urological carcinoma with an increasing incidence in Indonesia and all around the world. Early diagnosis can greatly affect treatment outcomes and increase life expectancy. Several biomarkers for detecting prostate cancer have been studied and showed great promise. This study aims to analyze prostate cancer antigen 3 (PCA3) as well as transmembrane serine protease 2:ERG (TMPRSS2:ERG) for diagnosing and serving as urine biomarkers in predicting prostate cancer incidences. We conducted an analytical study to assess the utility of PCA3 and TMPRSS2:ERG for detecting prostate cancer. Thirty samples were included in this study to see the utilization of PCA3 and TMPRSS2:ERG as diagnostic biomarkers of prostate cancer. A urine sample was taken and the PCA3 test was performed using the PCA3 PROGENSA test, while the TMPRSS2:ERG was performed using the chemiluminescent DNA probe method with a hybridization protection test. The average age of the subject was 61.07±8.3 years. Based on calculations using the Mann-Whitney test, there was a significant relationship between prostate-Specific Antigen (PSA) overexpression (p